At present, the anti-vascular endothelial growth factor (VEGF) agent is used as the first-line treatment for nAMD and is also applied to other retinal diseases such as diabetic macular edema, macular edema secondary to retinal vein occlusion and myopic choroidal neovascularization (mCNV) [13]. This evidence concerns the gene VEGFA and Abnormal retinal morphology.